FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085247930> ?p ?o ?g. }

• W2085247930 endingPage "2440" @default.
• W2085247930 startingPage "2434" @default.
• W2085247930 abstract "Polo-like kinase 1 (Plk1) has an important role in mitosis. Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to determine its maximum tolerated dose (MTD) in Asian patients with advanced solid tumours.Patients were enrolled simultaneously into two 3-week schedules of volasertib: a 2-h infusion on day 1 (schedule A) or days 1 and 8 (schedule B). Dose escalation followed a 3+3 design. The MTD was determined based on dose-limiting toxicities (DLT) in the first treatment course.Among 59 treated patients, the most common first course DLTs were reversible thrombocytopenia, neutropenia and febrile neutropenia; MTDs were 300 mg for schedule A and 150 mg for schedule B. Volasertib exhibited multi-exponential pharmacokinetics (PK), a long terminal half-life of ∼135 h, a large volume of distribution (>3000 l), and a moderate clearance. Partial responses were observed in two pre-treated patients (ureteral cancer; melanoma). Volasertib was generally well tolerated, with an adverse event profile consistent with its antimitotic mode of action and a favourable PK profile.These data support further development of volasertib and a harmonised dosing for Asian and Caucasian patients." @default.
• W2085247930 created "2016-06-24" @default.
• W2085247930 creator A5006281861 @default.
• W2085247930 creator A5008487735 @default.
• W2085247930 creator A5009846821 @default.
• W2085247930 creator A5012285379 @default.
• W2085247930 creator A5013592199 @default.
• W2085247930 creator A5017953971 @default.
• W2085247930 creator A5044355806 @default.
• W2085247930 creator A5052962058 @default.
• W2085247930 creator A5072263190 @default.
• W2085247930 creator A5077232595 @default.
• W2085247930 creator A5086346357 @default.
• W2085247930 creator A5090591171 @default.
• W2085247930 date "2014-04-22" @default.
• W2085247930 modified "2023-10-17" @default.
• W2085247930 title "A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies" @default.
• W2085247930 cites W1557877432 @default.
• W2085247930 cites W2004981153 @default.
• W2085247930 cites W2020411912 @default.
• W2085247930 cites W2020516698 @default.
• W2085247930 cites W2023678160 @default.
• W2085247930 cites W2037874673 @default.
• W2085247930 cites W2080377650 @default.
• W2085247930 cites W2102126248 @default.
• W2085247930 cites W2108268005 @default.
• W2085247930 cites W2113920379 @default.
• W2085247930 cites W2116068077 @default.
• W2085247930 cites W2121344811 @default.
• W2085247930 cites W2139248078 @default.
• W2085247930 cites W2149425953 @default.
• W2085247930 cites W2158509618 @default.
• W2085247930 cites W2167831982 @default.
• W2085247930 cites W2168282983 @default.
• W2085247930 cites W2507926833 @default.
• W2085247930 cites W4293241248 @default.
• W2085247930 doi "https://doi.org/10.1038/bjc.2014.195" @default.
• W2085247930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4021529" @default.
• W2085247930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24755882" @default.
• W2085247930 hasPublicationYear "2014" @default.
• W2085247930 type Work @default.
• W2085247930 sameAs 2085247930 @default.
• W2085247930 citedByCount "61" @default.
• W2085247930 countsByYear W20852479302015 @default.
• W2085247930 countsByYear W20852479302016 @default.
• W2085247930 countsByYear W20852479302017 @default.
• W2085247930 countsByYear W20852479302018 @default.
• W2085247930 countsByYear W20852479302019 @default.
• W2085247930 countsByYear W20852479302020 @default.
• W2085247930 countsByYear W20852479302021 @default.
• W2085247930 countsByYear W20852479302022 @default.
• W2085247930 countsByYear W20852479302023 @default.
• W2085247930 crossrefType "journal-article" @default.
• W2085247930 hasAuthorship W2085247930A5006281861 @default.
• W2085247930 hasAuthorship W2085247930A5008487735 @default.
• W2085247930 hasAuthorship W2085247930A5009846821 @default.
• W2085247930 hasAuthorship W2085247930A5012285379 @default.
• W2085247930 hasAuthorship W2085247930A5013592199 @default.
• W2085247930 hasAuthorship W2085247930A5017953971 @default.
• W2085247930 hasAuthorship W2085247930A5044355806 @default.
• W2085247930 hasAuthorship W2085247930A5052962058 @default.
• W2085247930 hasAuthorship W2085247930A5072263190 @default.
• W2085247930 hasAuthorship W2085247930A5077232595 @default.
• W2085247930 hasAuthorship W2085247930A5086346357 @default.
• W2085247930 hasAuthorship W2085247930A5090591171 @default.
• W2085247930 hasBestOaLocation W20852479301 @default.
• W2085247930 hasConcept C112705442 @default.
• W2085247930 hasConcept C121608353 @default.
• W2085247930 hasConcept C126322002 @default.
• W2085247930 hasConcept C143998085 @default.
• W2085247930 hasConcept C146276462 @default.
• W2085247930 hasConcept C197934379 @default.
• W2085247930 hasConcept C2776694085 @default.
• W2085247930 hasConcept C2777063308 @default.
• W2085247930 hasConcept C2777288759 @default.
• W2085247930 hasConcept C2778850193 @default.
• W2085247930 hasConcept C29537977 @default.
• W2085247930 hasConcept C71924100 @default.
• W2085247930 hasConcept C84815855 @default.
• W2085247930 hasConcept C98274493 @default.
• W2085247930 hasConceptScore W2085247930C112705442 @default.
• W2085247930 hasConceptScore W2085247930C121608353 @default.
• W2085247930 hasConceptScore W2085247930C126322002 @default.
• W2085247930 hasConceptScore W2085247930C143998085 @default.
• W2085247930 hasConceptScore W2085247930C146276462 @default.
• W2085247930 hasConceptScore W2085247930C197934379 @default.
• W2085247930 hasConceptScore W2085247930C2776694085 @default.
• W2085247930 hasConceptScore W2085247930C2777063308 @default.
• W2085247930 hasConceptScore W2085247930C2777288759 @default.
• W2085247930 hasConceptScore W2085247930C2778850193 @default.
• W2085247930 hasConceptScore W2085247930C29537977 @default.
• W2085247930 hasConceptScore W2085247930C71924100 @default.
• W2085247930 hasConceptScore W2085247930C84815855 @default.
• W2085247930 hasConceptScore W2085247930C98274493 @default.
• W2085247930 hasIssue "10" @default.
• W2085247930 hasLocation W20852479301 @default.
• W2085247930 hasLocation W20852479302 @default.
• W2085247930 hasLocation W20852479303 @default.

• next